Cohort Study Summary of the Effects of Carboprost Tromethamine Combined with Oxytocin on Infant Outcome, Postpartum Hemorrhage and Uterine Involution of Parturients Undergoing Cesarean Section.

What Was Tested

This randomized controlled trial looks at Oxytocin.

To investigate the effects of carboprost tromethamine combined with oxytocin on infant outcome, postpartum hemorrhage, and uterine involution in parturients undergoing cesarean section.

Why It Was Studied

Carboprost tromethamine injection has a high safety factor in clinical application and has a good effect on uterine smooth muscle and vasoconstriction.

Who Took Part

PubMed tags the participants as women only.

How the Study Was Run

The researchers set it up as a randomized study.

The participants were allocated by chance, so the Oxytocin group and the comparison group should start out alike.

A total of 120 parturients undergone cesarean section in their hospital from February 2019 to April 2021 were selected as the object of study.

The parturients were randomly divided into control group (n = 60) and research group (n = 60).

The control group was treated with oxytocin, and the research group was treated with carboprost aminobutyriol combined with oxytocin.

The amount of maternal bleeding, uterine floor decline index, the end of lochia, poor rate of uterine involution, infant outcome, and the incidence of adverse drug reactions were compared between the two groups.

What Was Measured

The subject headings attached to it are Carboprost, Cesarean Section, Cohort Studies, Drug Combinations, Oxytocin, Postpartum Hemorrhage and Tromethamine.

What This Means in Plain Language

The paper is a randomized study of Oxytocin.

Results are reported in around 7 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2022 (Computational and mathematical methods in medicine), a journal based in United States.

More context: the Oxytocin compound page, all human trials.